best digital currency to invest in Top stories

US Treasury Department: US Treasury Secretary Yellen expressed appreciation for the close communication between the Ministry of Economic Affairs of Korea and the United States after the recent events in South Korea.Hengrui Pharma: HRS-4729 injection was approved for clinical trial. Hengrui Pharma announced that the company and its subsidiary Fujian Sheng Di Pharmaceutical Co., Ltd. received the Notice of Approval for Clinical Trial of HRS-4729 injection approved and issued by National Medical Products Administration. The drug is a polypeptide drug independently developed, and it is a GLP-1R/GIPR/GCGR triple agonist, which is suitable for obese or overweight patients. Up to now, HRS-4729 injection has invested about 19.56 million yuan in research and development.Ukraine said that the death toll from Russian attack on Zaporoge rose to seven. Ivan Fedoroff, head of military and political affairs in Zaporoge, Ukraine, said on the 11th that the Russian attack on Zaporoge on the 10th had caused seven deaths. (CCTV News)

Henan: Promote the research on new crystalline silicon solar cell technologies such as heterojunction and perovskite/stack. The General Office of the People's Government of Henan Province issued an implementation plan for accelerating the integration of source, grid, load and storage in Henan Province, which proposed to tackle key technical problems. Promote the research on new crystalline silicon solar cell technologies such as heterojunction and perovskite/stack, and improve the efficiency of new energy power generation. Accelerate technological breakthroughs such as core chips of power equipment and coordinated control of source and network, and improve the adaptability of power grid to new energy sources. Carry out research on key technologies of digitalization and intelligence of energy system, improve the matching degree between supply and demand of power supply and load, and solve the intermittent and unstable problems of new energy power generation. Develop a new generation of high-performance energy storage technologies such as solid-state batteries and sodium ion batteries, improve the flexible adjustment ability of the system, and solve the problem of time-space mismatch between power generation and power consumption. Accelerate research on high-precision new energy and flexible load power forecasting technology, economic optimization scheduling technology, and promote the establishment of an integrated laboratory for source, network, load and storage.Henan: Promote the research on new crystalline silicon solar cell technologies such as heterojunction and perovskite/stack. The General Office of the People's Government of Henan Province issued an implementation plan for accelerating the integration of source, grid, load and storage in Henan Province, which proposed to tackle key technical problems. Promote the research on new crystalline silicon solar cell technologies such as heterojunction and perovskite/stack, and improve the efficiency of new energy power generation. Accelerate technological breakthroughs such as core chips of power equipment and coordinated control of source and network, and improve the adaptability of power grid to new energy sources. Carry out research on key technologies of digitalization and intelligence of energy system, improve the matching degree between supply and demand of power supply and load, and solve the intermittent and unstable problems of new energy power generation. Develop a new generation of high-performance energy storage technologies such as solid-state batteries and sodium ion batteries, improve the flexible adjustment ability of the system, and solve the problem of time-space mismatch between power generation and power consumption. Accelerate research on high-precision new energy and flexible load power forecasting technology, economic optimization scheduling technology, and promote the establishment of an integrated laboratory for source, network, load and storage.Today, these stocks changed their main positions to increase electronic stocks and sell computer stocks, with a large amplitude.-Today, there are 22 stocks in A shares with an amplitude of more than 20%; -N Boyuan, Shenhao Technology, Panda Dairy and other stocks are among the top in amplitude; The turnover rate is high-today, there are 58 A-shares with a turnover rate of over 30%; -N Boyuan, Giant Wheel Intelligence, Tianyu Digital and other stocks have the highest turnover rate; Main funds-today, the main funds flowed into electronics, communications, real estate, non-ferrous metals, light industry manufacturing and other sectors, and flowed out of computers, machinery and equipment, non-bank finance, power equipment, automobiles and other sectors; -vision china, Jianghuai Automobile, Woer Nuclear Materials, Xinyisheng and Runxin Technology have the largest net inflows, with net inflows of 749 million yuan, 699 million yuan, 693 million yuan, 626 million yuan and 622 million yuan respectively; -Oriental Fortune, Shanzi Hi-Tech, Leo, Straight Flush, and Tianyue Mathematics have the largest net outflows, with net outflows of 2.295 billion yuan, 1.237 billion yuan, 1.131 billion yuan, 872 million yuan and 871 million yuan respectively.

The National Southeast Regional Emergency Rescue Center is about to be delivered. It was learned from the recent press conference held in Chaozhou, Guangdong that the National Southeast Regional Emergency Rescue Center is about to be delivered. The National Southeast Regional Emergency Rescue Center is located in Chao 'an District, Chaozhou City, Guangdong Province. It is one of the six national regional emergency rescue centers in China, focusing on the emergency rescue of typhoons and their secondary and derivative disasters. It has basic functions such as emergency command, comprehensive rescue, training drills, equipment storage and transportation, etc., to ensure that it can reach the disaster area in the shortest time to complete the difficult rescue task. (CCTV News) Hengrui Pharma: HRS-4729 injection was approved for clinical trial. Hengrui Pharma announced that the company and its subsidiary Fujian Sheng Di Pharmaceutical Co., Ltd. received the Notice of Approval for Clinical Trial of HRS-4729 injection approved and issued by National Medical Products Administration. The drug is a polypeptide drug independently developed, and it is a GLP-1R/GIPR/GCGR triple agonist, which is suitable for obese or overweight patients. Up to now, HRS-4729 injection has invested about 19.56 million yuan in research and development.